221 related articles for article (PubMed ID: 29259533)
1. Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan.
Halioua-Haubold CL; Peyer JG; Smith JA; Arshad Z; Scholz M; Brindley DA; MacLaren RE
Yale J Biol Med; 2017 Dec; 90(4):683-693. PubMed ID: 29259533
[TBL] [Abstract][Full Text] [Related]
2. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
[TBL] [Abstract][Full Text] [Related]
3. Analysis and comparative evaluation of expedited programs for gene therapy products: insights from the United States, the European Union, Japan, and South Korea.
Jeong H; Purja S; Kim E
Gene Ther; 2024 May; 31(5-6):242-254. PubMed ID: 38200263
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European Union.
Narayanan G; Cossu G; Galli MC; Flory E; Ovelgonne H; Salmikangas P; Schneider CK; Trouvin JH
Hum Gene Ther Clin Dev; 2014 Mar; 25(1):1-6. PubMed ID: 24649836
[TBL] [Abstract][Full Text] [Related]
5. Access to advanced therapy medicinal products in the EU: where do we stand?
Mahalatchimy A
Eur J Health Law; 2011 May; 18(3):305-17. PubMed ID: 21870592
[TBL] [Abstract][Full Text] [Related]
6. Challenges with advanced therapy medicinal products and how to meet them.
; ; Schneider CK; Salmikangas P; Jilma B; Flamion B; Todorova LR; Paphitou A; Haunerova I; Maimets T; Trouvin JH; Flory E; Tsiftsoglou A; Sarkadi B; Gudmundsson K; O'Donovan M; Migliaccio G; Ancāns J; Maciulaitis R; Robert JL; Samuel A; Ovelgönne JH; Hystad M; Fal AM; Lima BS; Moraru AS; Turcáni P; Zorec R; Ruiz S; Akerblom L; Narayanan G; Kent A; Bignami F; Dickson JG; Niederwieser D; Figuerola-Santos MA; Reischl IG; Beuneu C; Georgiev R; Vassiliou M; Pychova A; Clausen M; Methuen T; Lucas S; Schüssler-Lenz M; Kokkas V; Buzás Z; MacAleenan N; Galli MC; Linē A; Gulbinovic J; Berchem G; Fraczek M; Menezes-Ferreira M; Vilceanu N; Hrubisko M; Marinko P; Timón M; Cheng W; Crosbie GA; Meade N; di Paola ML; VandenDriessche T; Ljungman P; D'Apote L; Oliver-Diaz O; Büttel I; Celis P
Nat Rev Drug Discov; 2010 Mar; 9(3):195-201. PubMed ID: 20190786
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
Renner M; Anliker B; Sanzenbacher R; Schuele S
Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
[TBL] [Abstract][Full Text] [Related]
8. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.
Nagai S
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382625
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of GMO regulatory requirements for AAV vectors in the EU and Japan focusing on the shedding data and containment measures.
Mizoguchi H; Fleischmann T; Komuro M; Hirai T; Ikeda A; Saito K; Watahiki T; Tajima G
Expert Opin Biol Ther; 2024 Jun; 24(6):529-542. PubMed ID: 38919146
[TBL] [Abstract][Full Text] [Related]
10. Encountering Challenges with the EU Regulation on Advance Therapy Medical Products.
Mansnérus J
Eur J Health Law; 2015 Dec; 22(5):426-61. PubMed ID: 26665690
[TBL] [Abstract][Full Text] [Related]
11. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
12. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?
Boráň T; Menezes-Ferreira M; Reischl I; Celis P; Ferry N; Gänsbacher B; Krafft H; Lipucci di Paola M; Sladowski D; Salmikangas P
Hum Gene Ther Clin Dev; 2017 Sep; 28(3):126-135. PubMed ID: 28510497
[TBL] [Abstract][Full Text] [Related]
13. Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera.
Watanabe N; Yano K; Tsuyuki K; Okano T; Yamato M
Mol Ther Methods Clin Dev; 2015; 2():14066. PubMed ID: 26052534
[TBL] [Abstract][Full Text] [Related]
14. A Regulatory Risk-Based Approach to ATMP/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations.
Salazar-Fontana LI
Front Med (Lausanne); 2022; 9():855100. PubMed ID: 35646952
[TBL] [Abstract][Full Text] [Related]
15. Post-marketing authorisation safety and efficacy surveillance of advanced therapy medicinal products in Brazil, the European Union, the United States and Japan.
Gomes KLG; da Silva RE; da Silva JB; Bosio CGP; Novaes MRCG
Cytotherapy; 2023 Oct; 25(10):1113-1123. PubMed ID: 37436339
[TBL] [Abstract][Full Text] [Related]
16. Overview of the clinical application of regenerative medicine products in Japan.
Tsubouchi M; Matsui S; Banno Y; Kurokawa K; Kawakami K
Health Policy; 2008 Oct; 88(1):62-72. PubMed ID: 18395290
[TBL] [Abstract][Full Text] [Related]
17. Environmental risk assessment of advanced therapies containing genetically modified organisms in the EU.
Whomsley R; Palmi Reig V; Hidalgo-Simon A
Br J Clin Pharmacol; 2021 Jun; 87(6):2450-2458. PubMed ID: 33600022
[TBL] [Abstract][Full Text] [Related]
18. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
19. Regulatory structures for gene therapy medicinal products in the European Union.
Klug B; Celis P; Carr M; Reinhardt J
Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
[TBL] [Abstract][Full Text] [Related]
20. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
